Fig. 6

Involvements of JNK, ERK1/2, p38 and NF-κB in the induction COX-2, IL-1β and IL-6 by IL-33 in human amnion fibroblasts. (A–D) Blockade of IL-33 (100 ng/mL; 8 h)-induced COX-2 expression and PGE2 production by JNK inhibitor SP600125 (SP; 20 µM; A), ERK1/2 inhibitor PD98059 (PD; 20 µM; B), p38 inhibitor SB203580 (SB; 10 µM; C) and NF-κB inhibitor JSH-23 (JSH; 10 µM; D). n = 3. Top panels are the representative immunoblots and bottom panels are the average data. (E–H) Blockade of IL-33 (100 ng/mL; 8 h)-induced IL-1β and IL-6 production by JNK inhibitor SP600125 (SP; 20 µM; E), ERK1/2 inhibitor PD98059 (PD; 20 µM; F), p38 inhibitor SB203580 (SB; 10 µM; G) and NF-κB inhibitor JSH-23 (JSH; 10 µM; H). n = 4–5. Data are mean ± SEM. Statistical analysis was performed with one-way ANOVA test followed by the Newman-Keuls multiple comparison test. *p < 0.05, **p < 0.01 vs. 0 ng/mL; #p < 0.05, ##p < 0.01 vs. IL-33-treated group